Physician profile
John Llewelyn
NPI 1326497066
$6,578.83
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23.95 · 2020: $168 · 2021: $146 · 2022: $82.25 · 2023: $6,126 · 2024: $32.77.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $6,000 · Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $6,000.00 |
| Food and Beverage | $158.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,000.00 | 2023 | Davinci Xi |
| Abbvie INC. | $287.46 | 2020-2024 | |
| Channel Medsystems, INC. | $49.83 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.97 | 2019-2020 | |
| Coloplast Corp | $33.68 | 2023 | Saffron |
| Daiichi Sankyo INC. | $26.92 | 2023 | Injectafer |
| Medtronic, INC. | $23.03 | 2023 | Truclear |
| Astellas Pharma US INC | $17.79 | 2020 | |
| Lupin INC. | $16.67 | 2020 | |
| Dermira, INC. | $16.56 | 2020 | |
| Pfizer INC. | $16.03 | 2024 | |
| Coopersurgical, INC. | $15.96 | 2022 | |
| Mylan Pharmaceuticals INC. | $14.07 | 2020 | |
| Teleflex LLC | $13.82 | 2021 | |
| Alexion Pharmaceuticals, INC. | $12.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Llewelyn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.